JP2024506385A - Ｇｄｃ－９５４５及びｇｄｃ－００７７を含む併用療法を使用する乳がんの治療 - Google Patents

Ｇｄｃ－９５４５及びｇｄｃ－００７７を含む併用療法を使用する乳がんの治療 Download PDF

Info

Publication number
JP2024506385A
JP2024506385A JP2023548874A JP2023548874A JP2024506385A JP 2024506385 A JP2024506385 A JP 2024506385A JP 2023548874 A JP2023548874 A JP 2023548874A JP 2023548874 A JP2023548874 A JP 2023548874A JP 2024506385 A JP2024506385 A JP 2024506385A
Authority
JP
Japan
Prior art keywords
gdc
patient
combination therapy
months
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548874A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022177844A5 (https=
JP2024506385A5 (https=
Inventor
シアラ メトカーフ，
シヤオチン ワン，
ウェイ チョウ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80953424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2024506385(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2024506385A publication Critical patent/JP2024506385A/ja
Publication of JPWO2022177844A5 publication Critical patent/JPWO2022177844A5/ja
Publication of JP2024506385A5 publication Critical patent/JP2024506385A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2023548874A 2021-02-16 2022-02-14 Ｇｄｃ－９５４５及びｇｄｃ－００７７を含む併用療法を使用する乳がんの治療 Pending JP2024506385A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163149944P 2021-02-16 2021-02-16
US63/149,944 2021-02-16
PCT/US2022/016270 WO2022177844A1 (en) 2021-02-16 2022-02-14 Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077

Publications (3)

Publication Number Publication Date
JP2024506385A true JP2024506385A (ja) 2024-02-13
JPWO2022177844A5 JPWO2022177844A5 (https=) 2025-02-18
JP2024506385A5 JP2024506385A5 (https=) 2025-02-18

Family

ID=80953424

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548874A Pending JP2024506385A (ja) 2021-02-16 2022-02-14 Ｇｄｃ－９５４５及びｇｄｃ－００７７を含む併用療法を使用する乳がんの治療

Country Status (8)

Country Link
US (1) US20230381155A1 (https=)
EP (1) EP4294395B1 (https=)
JP (1) JP2024506385A (https=)
CN (1) CN117377472A (https=)
ES (1) ES3030540T3 (https=)
PL (1) PL4294395T3 (https=)
TW (1) TWI808648B (https=)
WO (1) WO2022177844A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025163068A (ja) * 2022-11-02 2025-10-28 ペトラ・ファーマ・コーポレイション 疾患の治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリックポケット及びオルソステリックポケットの標的化
KR20250107982A (ko) * 2022-11-02 2025-07-14 페트라 파마 코포레이션 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 및 오르토스테릭 포켓 표적화

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018519307A (ja) * 2015-07-02 2018-07-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
WO2019245974A1 (en) * 2018-06-21 2019-12-26 Genentech, Inc. Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
WO2020023297A1 (en) * 2018-07-23 2020-01-30 Genentech, Inc. Methods of treating cancer with pi3k inhibitor, gdc-0077

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102785474B1 (ko) 2014-12-18 2025-03-26 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
US20170362228A1 (en) * 2016-06-16 2017-12-21 Genentech, Inc. TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
CA3109090A1 (en) 2018-08-17 2020-02-20 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for the treatment of breast cancer
CN115175679A (zh) * 2020-03-06 2022-10-11 奥列马制药公司 治疗雌激素受体相关疾病的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018519307A (ja) * 2015-07-02 2018-07-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
WO2019245974A1 (en) * 2018-06-21 2019-12-26 Genentech, Inc. Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
WO2020023297A1 (en) * 2018-07-23 2020-01-30 Genentech, Inc. Methods of treating cancer with pi3k inhibitor, gdc-0077

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. Vol.79, No.4_Supplement, JPN6025051023, 2019, pages 5 - 04, ISSN: 0005754030 *
SCIENCE, vol. 366, no. 6466, JPN6025051024, 2019, pages 714 - 723, ISSN: 0005754031 *

Also Published As

Publication number Publication date
TWI808648B (zh) 2023-07-11
ES3030540T3 (en) 2025-06-30
EP4294395B1 (en) 2025-03-26
TW202237100A (zh) 2022-10-01
WO2022177844A1 (en) 2022-08-25
CN117377472A (zh) 2024-01-09
US20230381155A1 (en) 2023-11-30
EP4294395A1 (en) 2023-12-27
EP4294395C0 (en) 2025-03-26
PL4294395T3 (pl) 2025-06-23

Similar Documents

Publication Publication Date Title
US20230381155A1 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077
JP2022544485A (ja) Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置
US20240173306A1 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
US20230381156A1 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and ipatasertib
TWI828060B (zh) 使用包含gdc-9545及阿貝西尼或瑞博西尼之組合療法治療乳癌
HK40101173A (zh) 使用包括gdc-9545和gdc-0077的组合疗法治疗乳腺癌
HK40129153A (zh) 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌
HK40084792B (zh) 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌
HK40101825A (zh) 使用包括gdc-9545和依帕他赛的组合疗法治疗乳腺癌
HK40098151A (zh) 使用包括gdc-9545以及阿贝西利或者瑞博西尼的组合疗法治疗乳腺癌
HK40084792A (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260316